Literature DB >> 17434043

Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies.

Gregory J Fulchiero1, Heather Salvaggio, Joseph J Drabick, Kevin Staveley-O'Carroll, Elizabeth M Billingsley, James G Marks, Klaus F Helm.   

Abstract

We report two cases of late recurrence of eruptive locoregional metastatic melanoma occurring 6 and 9 years after definitive surgical treatment. Each case (stage IB and IA) occurred after initiation of the subcutaneous anti-tumor necrosis factor medications etanercept and adalimumab, respectively. We discuss the association of immune suppression and melanoma. These cases illustrate a previously unrecognized and potentially causal relationship between tumor necrosis factor-alpha inhibition and reactivation of latent melanoma.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17434043     DOI： 10.1016/j.jaad.2006.12.024

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


  16 in total

1.  Risk of Cancer Recurrence Among Individuals Exposed to Antitumor Necrosis Factor Therapy: A Systematic Review and Meta-Analysis of Observational Studies.

Authors:  Dejan Micic; Yuga Komaki; Aleksandar Alavanja; David T Rubin; Atsushi Sakuraba
Journal:  J Clin Gastroenterol       Date:  2019-01       Impact factor: 3.062

Review 2.  Roles of the immune system in skin cancer.

Authors:  S Rangwala; K Y Tsai
Journal:  Br J Dermatol       Date:  2011-11       Impact factor: 9.302

3.  Association of melanoma and natalizumab therapy in the Italian MS population: a second case report.

Authors:  A Laroni; M Bedognetti; A Uccelli; E Capello; G L Mancardi
Journal:  Neurol Sci       Date:  2010-11-05       Impact factor: 3.307

4.  [Long term treatment of psoriasis with TNF-alpha antagonists. Occurrence of malignant melanoma].

Authors:  L Kowalzick; L Eickenscheidt; M Komar; E Schaarschmidt
Journal:  Hautarzt       Date:  2009-08       Impact factor: 0.751

5.  Regression of advanced melanoma upon withdrawal of immunosuppression: case series and literature review.

Authors:  P Dillon; N Thomas; N Sharpless; F Collichio
Journal:  Med Oncol       Date:  2009-11-05       Impact factor: 3.064

6.  More questions than answers: a call for a moratorium on the use of intravitreal infliximab outside of a well-designed trial.

Authors:  Jose S Pulido; Jose E Pulido; Clement J Michet; Richard G Vile
Journal:  Retina       Date:  2010-01       Impact factor: 4.256

Review 7.  TNF inhibitors to treat ulcerative colitis in a metastatic breast cancer patient: a case report and literature review.

Authors:  Ruwaida Ben Musa; Lydia Usha; John Hibbeln; Ece A Mutlu
Journal:  World J Gastroenterol       Date:  2014-05-21       Impact factor: 5.742

8.  Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease.

Authors:  Millie D Long; Christopher F Martin; Clare A Pipkin; Hans H Herfarth; Robert S Sandler; Michael D Kappelman
Journal:  Gastroenterology       Date:  2012-05-11       Impact factor: 22.682

Review 9.  Anti-TNF agents in patients with inflammatory bowel disease and malignant melanoma--challenges in management.

Authors:  Jungmin Lee; Kofi Clarke
Journal:  Int J Colorectal Dis       Date:  2015-09-08       Impact factor: 2.571

10.  Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature.

Authors:  Jochen Schmitt; Gottfried Wozel
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.